A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression

American Journal of Psychiatry

Volumn 157, Issue 3, 2000, Pages 344-350

  McGrath, Patrick J ^a   Stewart, Jonathan W ^a   Janal, Malvin N ^a   Petkova, Eva ^a   Quitkin, Frederic M ^a   Klein, Donald F ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HEALTH STATUS; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PERSONALITY INVENTORY; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034057519     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.3.344     Document Type: Article

References (37)

1. Joyce PR, Paykel ES: Predictors of drug response in depression. Arch Gen Psychiatry 1989; 46:89-99
2. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF: Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45:129-137
3. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klein DF, Rabkin JG, Markowitz JS, Wager SG: Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145:306-311
4. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF: Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989; 46:787-793
5. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF: Atypical depression, panic attacks - response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990; 47:935-941
6. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wager SG, Nunes E, Klein DF: Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991; 48:319-323
7. Asnis GM, McGinn LK, Sanderson WC: Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995; 152:31-36
8. Quitkin FM, Rabkin JG, Stewart JW, McGrath PJ, Harrison WM, Davies M, Goetz R, Puig-Antich J: Sleep of atypical depressives. J Affect Disord 1985; 8:61-67
9. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM: Atypical depression: a valid clinical entity? Psychiatr Clin North Am 1993; 16:479-496
10. Rabkin JG, Stewart JW, Quitkin FM, McGrath PJ, Harrison WM, Klein DF: Should atypical depression be included in DSM-IV?, in DSM-IV Source Book, vol 2. Edited by Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW. Washington, DC, American Psychiatric Association, 1994, pp 239-260
11. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC: The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996; 53:391-399
12. Sullivan PF, Kessler RC, Kendler KS: Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. Am J Psychiatry 1998; 155:1398-1406
13. Horwath E, Johnson J, Weissman MM, Hornig CD: The validity of major depression with atypical features based on a community survey. J Affect Disord 1992; 26:117-126
14. Zisook S, Shuchter SR, Gallagher T, Sledge P: Atypical depression in an outpatient psychiatric population. Depression 1993; 1:26-274
15. Robertson HA, Lam RW, Stewart JN, Yatham LN, Tam EM, Zis AP: Atypical depressive symptoms and clusters in unipolar and bipolar depression. Acta Psychiatr Scand 1996; 94: 421-427
16. Levitan RD, Lesage A, Parikh SV, Goering P, Kennedy SH: Reversed neurovegetative symptoms of depression: a community study of Ontario. Am J Psychiatry 1997, 154:934-940
17. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M: Course and treatment of atypical depression. J Clin Psychiatry 1999; 59(suppl 18):5-9
18. Agosti V, Stewart JW, Quitkin FM, Rabkin JG, McGrath PJ, Markowitz J: Factors associated with premature medication discontinuation among responders to an MAOI or tricyclic antidepressant. J Clin Psychiatry 1988; 49:196-198
19. Reimherr FW, Wood DR, Byerley B, Brainard J, Grosser BI: Characteristics of responders to fluoxeline. Psychopharmacol Bull 1984; 20:90-92
20. Lonnquist J, Sihvo S, Syvalahti E, Kiviruusu O: Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994; 32:169-177
21. Pande AC, Haskett RF, Greden JF: Double-blind comparison of fluoxetine and phenelzine in atypical depression. Biol Psychiatry 1991; 29:117A-118A
22. Stratta P, Bolino F, Cupillari M, Casacchia M: A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991; 6:193-196
23. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Welikson K, Rabkin JG, Nunes E, Wager S, Tricamo E, Quitkin FM, Klein DF: The predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992; 12:197-202
24. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
25. McGlashan T (ed): The Documentation of Clinical Psychotropic Drug Trials. Rockville, Md, National Institute of Mental Health, 1973
26. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
27. Ware JE: SF-36 Health Survey: Manual and Interpretation Guide. Boston, New England Medical Center, Health Institute, 1993
28. Neyman J, Johnson PO: Tests of certain linear hypotheses and their application to some educational problems. Statistical Res Memoirs 1936; 1:57-93
29. Potthoff RF: On the Johnson-Neyman technique and some extensions thereof. Psychometrika 1964; 29:241-256
30. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J: The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262:914-919
31. Mitchell MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250-1256
32. Stahl SM: Basic psychopharmacology of antidepressants, part 1 : antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59(suppl 4):5-14
33. Goodnick PJ, Extein IL: Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989; 1:119-122
34. McGrath PJ, Stewart JW, Quitkin FM, Ocepek-Welikson K, Klein DF: Does imipramine worsen atypical depression? J Clin Psychopharmacol 1991; 11:270-272
35. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P: Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55:334-345
36. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen JN, Pierredon MA: The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988; 3:69-76
37. Lane R, Baldwin D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: a review J Clin Psychopharmacol 1997; 17:208-221